Motti Hakim

Motti Hakim is a notable inventor based in Kibbutz Gazit, Israel. He has made significant contributions to the field of cancer treatment through his innovative research and development of monoclonal antibodies. With a total of 4 patents to his name, Hakim continues to push the boundaries of medical science.

Latest Patents

One of Hakim's latest patents focuses on methods of use for anti-ILT2 antibodies. This invention provides monoclonal antibodies, or antigen-binding portions thereof, against ILT2, along with pharmaceutical compositions that include these antibodies. The patent also outlines methods for treating cancer by administering these antibodies or compositions. Additionally, it covers combination treatments and patient selection strategies. Another significant patent involves methods for decreasing soluble immune receptor CD28. This invention presents methods for treating cancer and enhancing immunotherapies by reducing soluble immune receptor levels. It includes agents that bind to the membranal immune receptor and inhibit its proteolytic cleavage, as well as agents that bind to the soluble immune receptor without acting as receptor agonists or antagonists.

Career Highlights

Throughout his career, Motti Hakim has worked with various companies, including Biond Biologics Ltd. and Biond Biologies Ltd. His work in these organizations has contributed to advancements in biopharmaceuticals and cancer therapies.

Collaborations

Hakim has collaborated with notable colleagues such as Dana Haves Ziv and Dror Alishekevitz. These partnerships have fostered innovation and development in his research endeavors.

Conclusion

Motti Hakim's contributions to cancer treatment through his patents and collaborations highlight his role as a leading inventor in the field. His work continues to inspire advancements in medical science and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.